You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Affordable sialoglycans and associated reagents for expanded chemoenzymatic production
SBC: Integrated Micro-Chromatography Systems, Inc. Topic: 300Project Summary Sialoglycans are sialic acid-containing oligosaccharides that play important biological roles in human biology and pathology and are indispensable molecular probes for research related to bacterial and viral infection, cancer metastasis, immune regulation, etc. The multifaceted functions of sialoglycans in human milk are also being explored. Nevertheless, sialoglycan-related resear ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Aminoglycosides with reduced ototoxicity
SBC: NUBAD LLC Topic: NIAIDPROJECT SUMMARYAminoglycosides are one of the cheapest and well-known antibiotics in clinical use for over 70 years, but one of the major limitations in their use is their ototoxicity. We are developing fast and low-cost methods to develop aminoglycosides with anti-ribosomal activities and reduced toxicity. In this project, we will identify novel aminoglycoside antibacterials, that show reduced ot ...
STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
Application of PPODA-QT for embolization of aneurysms
SBC: ANEUVAS TECHNOLOGIES INC Topic: 101PROJECT SUMMARY/ABSTRACTA cerebral aneurysm is an abnormal enlargement or pouch that forms from a weakened vessel segment in the brain. Often going unnoticed and untreated, an aneurysm can cause a sudden and catastrophic hemorrhage or stroke. Approximately 15 % of patients die from an aneurysm rupture even before receiving medical attention and 25 % of patients die despite medical treatment. Patie ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
A Rapid assay for RNA targeted drugs: Instrumentation Supplement
SBC: NUBAD LLC Topic: 300DESCRIPTION provided by applicant Some of the most significant therapies that treat disease target nucleic acids Drugs that target nucleic acid include cancer drugs antibiotics and antivirals Combined these classes of drugs have annual sales worldwide of $ billion Antibiotics that target nucleic acids account for $ billion of the $ billion of sales annuall for all antibiotics an ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Assessing the Bite Counter as a Tool for Food Intake Monitoring: Phase II
SBC: BITE TECHNOLOGIES, LLC Topic: 300DESCRIPTION provided by applicant Self monitoring has been described as the andquot cornerstone of the behavioral treatment of obesityandquot Consistent self monitoring of energy intake is associated with improved dietary adherence and weight loss and maintenance The problem is that individuals are notoriously bad at self monitoring their intake and suffer from an underreporting bias The s ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Commercialization of a Diagnostic test for amyotrophic lateral sclerosis (ALS)
SBC: IRON HORSE DIAGNOSTICS, INC. Topic: 101DESCRIPTION provided by applicant Amyotrophic lateral sclerosis ALS or Lou Gehrigandapos s disease is a fatal neurodegenerative disease with a typical lifespan of years after diagnosis The initial symptoms can be similar to many other neurologic disorders and often begin with limb weakness muscle fasciculations or increasing difficulties in speech or breathing No definitive diagnost ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Continuous monitoring of anti-fibrinolytic therapy in cardiovascular surgery
SBC: Micro Vide, LLC Topic: NHLBIDESCRIPTION (provided by applicant): A major cause of morbidity and mortality in cardiovascular surgery is excessive bleeding post- operatively, which is commonly managed by pharmacologically modifying clot degradation (fibrinolysis), through inhibition of plasmin activity (PLact). However, the only FDA approved and most commonly used inhibitor of PLact in cardiovascular surgery, while effective i ...
STTR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health -
Critical angle reflection imaging for label-free quantification of molecular interactions
SBC: BIOSENSING INSTRUMENT INC Topic: 400TITLE: Critical angle reflection imaging (CARi) for label-free quantification of molecular interactions SUMMARYMeasuring molecular interactions of proteins are critical for understanding protein functions and cellular processes, for discovery and validating biomarkers, and for developing and screening drugs. In particular, membrane proteins play key roles in many cellular functions and are the lar ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Cultural Competence in the Context of Type 2 Diabetes
SBC: MEDICAL DIRECTIONS, INC. Topic: N/ADESCRIPTION (provided by applicant): While the overall health of Americans has improved, ethnic minorities (particularly African Americans, Hispanics/Latinos, American Indians, Alaska Natives, Asians, and Pacific Islanders) continue to suffer from poorer health outcomes. During Phase I we developed and tested an interactive, case-based, online CME program designed to improve physicians' ability to ...
STTR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health -
Development of Non-Catalytic Peptide Inhibitors of Focal Adhesion Kinase (FAK) for Use in Melanoma
SBC: Faknostics, LLC Topic: 102Abstract Melanoma is the deadliest form of skin cancer, affecting an estimated 1.2 million Americans. The disease has a high propensity for dissemination, and metastatic melanoma has a dismal prognosis, with a median survival of only 5–8 months. Healthcare costs for melanoma in 2021 are projected to reach nearly $4 billion, with a rising incidence rate. Despite considerable efforts in recent yea ...
STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health